Who is sponsoring NCT00528385?

NCT00528385 is sponsored by Medical University of Gdansk.

What drugs are being tested in NCT00528385?

Interventions in NCT00528385: Spironolactone (Spironol) 25 mg.

What condition does NCT00528385 study?

NCT00528385 studies Chronic Kidney Disease, Proteinuria.

Is NCT00528385 still recruiting?

NCT00528385 is currently completed. Last updated 11 September 2007.

Last reviewed 2007-09-11 · How we verify

NCT00528385

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Adding Aldosterone Receptor Blocker to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria

Completed NA Last updated 11 September 2007

What this trial tests

NA trial testing Spironolactone (Spironol) 25 mg in Chronic Kidney Disease. Completed.

Timeline

1 March 2005

Quick facts

Lead sponsor	Medical University of Gdansk
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Start date	1 March 2005

Drugs / interventions tested

Spironolactone (Spironol) 25 mg — full drug profile →

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Proteinuria — all drugs for Proteinuria →

Sponsor

Medical University of Gdansk

Who can join

Adults 18 to 60, any sex, with Chronic Kidney Disease or Proteinuria. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Investigate the antiproteinuric effect of adding aldosterone antagonist, spironolactone to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses.

Sponsor's own description

The main purpose of the study is find whether the addition of aldosterone antagonist, spironolactone to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY, Ruospo M, Natale P, Bolignano D, et al · · 2020 · cited 84× · PMID 33107592 · DOI 10.1002/14651858.cd007004.pub4

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other Medical University of Gdansk trials

Trials by the same sponsor.

NCT07521280 — State-Based Rehabilitation for Youth Athletes With Osgood-Schlatter or Sever-Related Apophyseal Pain · NA · not yet recruiting
NCT07446517 — Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes · NA · recruiting
NCT07449585 — Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
NCT07397208 — Assessment of the Repeatability of Sublingual Microcirculation Function Measurements in Healthy Volunteers and Criticall · not yet recruiting
NCT07345403 — GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Ana · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00528385 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Gdansk
Last refreshed: 11 September 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00528385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing